Clopidogrel dosing and role of genetics: ELEVATE-TIMI 56 trial

Revision as of 14:39, 25 November 2011 by Priyamvada Singh (talk | contribs) (Created page with "{{CMG}}; '''Associate Editor(s)-In-Chief:''' Priyamvada Singh, M.B.B.S. [mailto:psingh@perfuse.org] ==Overview== The results of the '''ELEVATE-TIMI 56 trial...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]

Overview

The results of the ELEVATE-TIMI 56 trial were recently presented in AHA 2011 held at Orlando, Florida.

ELEVATE-TIMI 56 trial

  • Hypothesis -
  • Study design
    • Patient population
      • Multicenter, randomized, double-blind trial
      • Duration of study - 1 years
      • Intervention -
      • Primary end point -
  • Limitations
  • Results -
  • Conclusions


References


Template:WikiDoc Sources